

anti-Glypican 3 (GC33) Mouse Monoclonal Primary Antibody

REF 790-4564

06483186001

IVD  50




Figure 1. anti-Glypican 3 (GC33) staining hepatocellular carcinoma

INTENDED USE

Anti-Glypican 3 (GC33) Mouse Monoclonal Primary Antibody (anti-Glypican 3 (GC33)) is directed against the heparan sulfate proteoglycan, glypican 3. This antibody may be used to aid in the differentiation of hepatocellular carcinoma from normal liver or benign lesions. The antibody is intended for qualitative staining in sections of formalin-fixed, paraffin-embedded tissue.

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information and proper controls.

This antibody is intended for *in vitro* diagnostic (IVD) use.

SUMMARY AND EXPLANATION

Anti-Glypican 3 (GC33) is a mouse monoclonal antibody produced against Glypican-3 (GPC3), a member of the glypican family of glycosylphosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans.¹ GPC3 protein is widely expressed in a variety of tissues during development but is suppressed in most adult tissues. Normal liver tissue and benign lesions such as dysplasia and cirrhotic nodules are typically negative for Glypican-3. Glypican-3 is overexpressed in hepatocellular carcinoma cells (HCC) and tissues and stimulates the growth of HCC cells by increasing autocrine/paracrine canonical Wnt signaling.¹⁻³ Additionally, GPC3 downregulates BMP7, a negative regulator of cell growth.⁴ GPC3 plays a role in regulating migration, adhesion, and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation.⁵

REAGENT PROVIDED

Anti-Glypican 3 (GC33) contains sufficient reagent for 50 tests.

One 5 mL dispenser of anti-Glypican 3 (GC33) contains approximately 8.4 µg of a mouse monoclonal antibody.

The antibody is diluted in phosphate buffered saline containing carrier protein and 0.05% ProClin 300, a preservative.

Total protein concentration of the reagent is approximately 3 mg/mL. Specific antibody concentration is approximately 1.7 µg/mL. There is no known non-specific antibody reactivity observed in this product.

Anti-Glypican 3 (GC33) is a mouse monoclonal antibody produced as cell culture supernatant.

Refer to the appropriate Ventana detection kit package insert for detailed descriptions of: (1) Principles of the Procedure, (2) Materials and Reagents Needed but Not Provided, (3) Specimen Collection and Preparation for Analysis, (4) Quality Control Procedures, (5) Troubleshooting, (6) Interpretation of Results, and (7) General Limitations.

MATERIALS REQUIRED BUT NOT PROVIDED

Staining reagents, such as Ventana detection kits (*ultraView* Universal DAB Detection Kit), and ancillary components, including negative and positive tissue control slides, are not provided.

STORAGE

Store at 2-8°C. Do not freeze.

To ensure proper reagent delivery and the stability of the antibody, replace the dispenser cap after every use and immediately place the dispenser in the refrigerator in an upright position.

Every antibody dispenser is expiration dated. When properly stored, the reagent is stable to the date indicated on the label. Do not use reagent beyond the expiration date.

SPECIMEN PREPARATION

Routinely processed, formalin-fixed, paraffin-embedded tissues are suitable for use with this primary antibody when used with Ventana detection kits and a Ventana BenchMark Series automated slide stainer. The recommended tissue fixative is 10% neutral buffered formalin.⁶ Slides should be stained immediately, as antigenicity of cut tissue sections may diminish over time.

It is recommended that positive and negative controls be run simultaneously with unknown specimens.

WARNINGS AND PRECAUTIONS

1. For *in vitro* diagnostic (IVD) use.
2. ProClin 300 is used as a preservative in this solution. It is classified as an irritant and may cause sensitization through skin contact. Take reasonable precautions when handling. Avoid contact of reagents with eyes, skin, and mucous membranes. Use protective clothing and gloves.
3. Materials of human or animal origin should be handled as biohazardous materials and disposed of with proper precautions.
4. Avoid contact of reagents with eyes and mucous membranes. If reagents come in contact with sensitive areas, wash with copious amounts of water.
5. Avoid microbial contamination of reagents as it may cause incorrect results.
6. Consult local and/or state authorities with regard to recommended method of disposal.
7. Refer to the Safety Data Sheet for additional information.

STAINING PROCEDURE

Ventana primary antibodies have been developed for use on a Ventana BenchMark Series automated slide stainer in combination with Ventana detection kits and accessories. A recommended staining protocol for the BenchMark XT and BenchMark ULTRA instruments with *ultraView* Universal DAB Detection Kit is listed in Table 1.

The parameters for the automated procedures can be displayed, printed and edited according to the procedure in the instrument's Operator's Manual. Refer to the appropriate Ventana detection kit package insert for more details regarding immunohistochemistry staining procedures.

Table 1. Recommended Staining Protocol for anti-Glypican 3 (GC33) with *ultraView* Universal DAB Detection Kit on a BenchMark XT and BenchMark ULTRA instrument.

Procedure Type	Method
Deparaffinization	Selected
Cell Conditioning (Antigen Unmasking)	Mild Cell Conditioning 1
Enzyme (Protease)	None required
Antibody (Primary)	BenchMark XT instrument 32 Minutes, 37°C BenchMark ULTRA instrument 32 Minutes, 36°C
Counterstain	Hematoxylin II, 4 Minutes
Post Counterstain	Bluing, 4 Minutes

Table 2. Recommended Staining Protocol for anti-Glypican 3 (GC33) with MIEW DAB Detection Kit on a BenchMark XT instrument.

Procedure Type	Method
Deparaffinization	Selected
Cell Conditioning (Antigen Unmasking)	Mild Cell Conditioning 1
Enzyme (Protease)	None required
Antibody (Primary)	BenchMark XT instrument 32 Minutes, 37°C
Counterstain	Hematoxylin II, 4 Minutes
Post Counterstain	Bluing, 4 Minutes

Due to variation in tissue fixation and processing, as well as general lab instrument and environmental conditions, it may be necessary to increase or decrease the primary antibody incubation, cell conditioning or protease pretreatment based on individual specimens, detection used, and reader preference. For further information on fixation variables, refer to "Immunohistochemistry Principles and Advances".⁷

POSITIVE TISSUE CONTROL

An example of positive control tissue for this antibody is placenta or hepatocellular carcinoma.

STAINING INTERPRETATION

The cellular staining pattern for anti-Glypican 3 (GC33) is granular cytoplasmic/membrane.

SPECIFIC LIMITATIONS

Uncharacterized staining was observed in the hypophysis and serous papillary adenocarcinoma.

This antibody has been optimized for a 32 minute incubation time on a BenchMark XT and BenchMark ULTRA instrument in combination with *ultraView* Universal DAB Detection Kit but the user must validate results obtained with this reagent.

PERFORMANCE CHARACTERISTICS

Staining tests for specificity, sensitivity, and reproducibility were conducted using anti-Glypican 3 (GC33) with *ultraView* Universal DAB Detection Kit on BenchMark XT and BenchMark ULTRA instruments.

Specificity

Table 3. Specificity of anti-Glypican 3 (GC33) was determined by testing formalin-fixed, paraffin-embedded normal tissues.

Tissue	# positive / total cases	Tissue	# positive / total cases
Cerebrum	0/3	Myeloid (bone marrow)	0/3
Cerebellum	0/3	Lung	0/3
Adrenal gland	0/3	Heart	0/3
Ovary	0/3	Esophagus	0/3
Pancreas	0/3	Stomach	0/3
Parathyroid gland	0/3	Small intestine	0/3
Hypophysis	3/3	Colon	0/3
Testis	0/3	Liver	0/49
Thyroid	0/3	Liver cirrhosis	0/11
Breast	0/3	Liver hepatitis	0/11
Spleen	0/3	Salivary gland	0/3

Tissue	# positive / total cases	Tissue	# positive / total cases
Tonsil	0/3	Kidney	0/3
Endometrium	0/3	Prostate	0/3
Skeletal muscle	0/3	Cervix	0/3
Nerve (sparse)	0/3	Skin	0/3
Thymus	0/3	Mesothelium and lung	0/3

Sensitivity

Table 4. Sensitivity of anti-Glypican 3 (GC33) was determined by testing a variety of formalin-fixed, paraffin-embedded neoplastic tissues.

Pathology	# positive / total cases
Glioblastoma	0/1
Atypical meningioma	0/1
Malignant ependymoma	0/1
Malignant oligodendroglioma	0/1
Serous papillary adenocarcinoma	1/1
Mucinous papillary adenocarcinoma	0/1
Islet cell carcinoma	0/1
Pancreatic adenocarcinoma	0/1
Seminoma	0/1
Embryonal carcinoma	0/1
Medullary carcinoma	0/1
Papillary carcinoma	0/1
Breast intraductal carcinoma	0/2
Breast invasive ductal carcinoma	0/1
Diffuse B-cell lymphoma	0/3
Lung small cell undifferentiated carcinoma	0/1
Lung squamous cell carcinoma	0/1
Lung adenocarcinoma	0/1
Esophageal squamous cell carcinoma	0/1
Esophageal adenocarcinoma	0/1
Gastric mucinous adenocarcinomas	0/1
Gastrointestinal adenocarcinoma	0/2
GIST	0/2
Cholangiocellular Carcinoma	0/12
Hepatocellular carcinoma	83/125
Hepatoblastoma	0/1
Renal clear cell carcinoma	0/1
Prostatic adenocarcinoma	0/2

Pathology	# positive / total cases
Leiomyoma	0/1
Endometrial adenocarcinoma	0/1
Endometrial clear cell carcinoma	0/1
Cervical squamous cell carcinoma	0/2
Embryonal rhabdomyosarcoma	0/1
Anal malignant melanoma	0/1
Basal cell carcinoma	0/1
Squamous cell carcinoma	0/1
Neurofibroma	0/1
Ganglioneuroblastoma	0/1
Epithelial malignant mesothelioma	0/1
Diffuse malignant lymphoma	0/1
Hodgkin lymphoma	0/1
Bladder transitional cell carcinoma	0/1
Low grade leiomyosarcoma	0/1
Osteosarcoma	0/1
Spindle cell rhabdomyosarcoma	0/1
Intermediate grade leiomyosarcoma	0/1
Rectal Adenocarcinoma	0/1
Rectal Interstitialoma	0/1

Reproducibility

Reproducibility studies for anti-Glypican 3 (GC33) were completed to demonstrate:

- Inter-lot reproducibility of the antibody.
- Intra-run and Inter-run reproducibility on a BenchMark XT instrument.
- Intra-platform reproducibility on the BenchMark XT instrument and the BenchMark ULTRA instrument.
- Inter-platform reproducibility between the BenchMark XT and BenchMark ULTRA instruments.

All studies met their acceptance criteria.

REFERENCES

1. Akutsu, N, Yamamoto H, et al. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. *World J Gastroenterol.* 2010;16,28;3521-3528.
2. Ishiguro, T, et al. Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer. *Cancer Res.* 2008;68,23;9832-9838.
3. Capurro MI, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. *Cancer Res.* 2005;65;6245-6254.
4. Midorikawa Y, Ishikawa S, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. *Int J Cancer.* 2003;103;455-465.
5. Stigliano I, et al. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. *Breast Cancer Res Treat.* 2009;114;251-262.
6. Carson F, Hladik C. *Histotechnology: A Self Instructional Text*, 3rd edition. Hong Kong: American Society for Clinical Pathology Press; 2009.

7. Roche PC, Hsi ED. *Immunohistochemistry-Principles and Advances. Manual of Clinical Laboratory Immunology*, 6th edition. In: NR Rose, ed. ASM Press; 2002.

INTELLECTUAL PROPERTY

BENCHMARK, *ultraView*, VENTANA, and the Ventana logo are trademarks of Roche.

All other trademarks are the property of their respective owners.

Ventana grants to the Purchaser a single use only license under U.S. Pat. Nos. 6045759, 6945128, and 7378058, and any foreign counterparts.

CONTACT INFORMATION



Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, Arizona 85755
USA

+1 520 887 2155
+1 800 227 2155 (USA)



www.ventanamed.com



Roche Diagnostics GmbH
Sandhofer Strasse 116
D-68305 Mannheim
Germany